Another Statin Well-tolerated for High Cholesterol

Susan Farley
Published Online: Sunday, July 1, 2007

In a multinational, placebo-controlled trial, rosuvastatin proved to be well-tolerated in patients with dyslipidemia. The 33-trial program included >16,800 patients who represented >25,000 patient-years of continuous exposure to rosuvastatin. The patients received 5 to 40 mg of the drug or placebo. Adverse events occurred in 52.1% of the rosuvastatin group and 51.8% of the placebo group, giving it an adverse-event profile similar to that of atorvastatin 10 to 80 mg, simvastatin 10 to 80 mg, and pravastatin 10 to 40 mg.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues